{"id":"https://openalex.org/W1996795014","doi":"https://doi.org/10.1021/jm020084h","title":"Discovery of an Opioid \u03ba Receptor Selective Pure Antagonist from a Library of N-Substituted 4\u03b2-Methyl-5-(3-hydroxyphenyl)morphans","display_name":"Discovery of an Opioid \u03ba Receptor Selective Pure Antagonist from a Library of N-Substituted 4\u03b2-Methyl-5-(3-hydroxyphenyl)morphans","publication_year":2002,"publication_date":"2002-07-04","ids":{"openalex":"https://openalex.org/W1996795014","doi":"https://doi.org/10.1021/jm020084h","mag":"1996795014","pmid":"https://pubmed.ncbi.nlm.nih.gov/12139463"},"language":"en","primary_location":{"id":"doi:10.1021/jm020084h","doi":"https://doi.org/10.1021/jm020084h","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm020084h","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058616888","display_name":"James B. Thomas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James B. Thomas","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","Cntr Drug Discovery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]},{"raw_affiliation_string":"Cntr Drug Discovery","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113436343","display_name":"Robert N. Atkinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert N. Atkinson","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045127959","display_name":"Nivedita D. Namdev","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nivedita Namdev","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103446078","display_name":"Richard B. Rothman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard B. Rothman","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013556769","display_name":"Kenneth M. Gigstad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth M. Gigstad","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089622533","display_name":"Scott E. Fix","orcid":"https://orcid.org/0000-0002-4581-488X","observed_orcids":["https://orcid.org/0000-0002-4581-488X"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott E. Fix","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","Cntr Drug Discovery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]},{"raw_affiliation_string":"Cntr Drug Discovery","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015241846","display_name":"S. Wayne Mascarella","orcid":"https://orcid.org/0000-0003-0092-8178","observed_orcids":["https://orcid.org/0000-0003-0092-8178"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Wayne Mascarella","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","Cntr Drug Discovery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]},{"raw_affiliation_string":"Cntr Drug Discovery","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077399123","display_name":"Jason P. Burgess","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason P. Burgess","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","Analytic Chem & Pharm"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]},{"raw_affiliation_string":"Analytic Chem & Pharm","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010259381","display_name":"N. Ariane Vinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Ariane Vinson","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103501601","display_name":"Heng Xu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heng Xu","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014962738","display_name":"Christina M. Dersch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christina M. Dersch","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011158918","display_name":"Buddy E. Cantrell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Buddy E. Cantrell","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109128143","display_name":"Dennis M. Zimmerman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis M. Zimmerman","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112366469","display_name":"F. Ivy Carroll","orcid":"https://orcid.org/0000-0001-9510-765X","observed_orcids":["https://orcid.org/0000-0001-9510-765X"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Ivy Carroll","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","Cntr Drug Discovery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, and Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 4628","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]},{"raw_affiliation_string":"Cntr Drug Discovery","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":1.2803,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.75693414,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"45","issue":"16","first_page":"3524","last_page":"3530"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.7910000085830688,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.7910000085830688,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10911","display_name":"Chemical Synthesis and Analysis","score":0.07349999994039536,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12649","display_name":"Alkaloids: synthesis and pharmacology","score":0.03849999979138374,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/kappa-opioid-receptor","display_name":"kappa opioid receptor","score":0.9440000057220459},{"id":"https://openalex.org/keywords/opioid-antagonists","display_name":"opioid antagonists","score":0.7720000147819519},{"id":"https://openalex.org/keywords/wet-chemical-synthesis","display_name":"wet chemical synthesis","score":0.6320000290870667},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.6439999938011169},{"id":"https://openalex.org/keywords/opioid-receptor-selectivity","display_name":"opioid receptor selectivity","score":0.34700000286102295}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8986221551895142},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.7879716157913208},{"id":"https://openalex.org/C2779886867","wikidata":"https://www.wikidata.org/wiki/Q421797","display_name":"Opioid receptor","level":4,"score":0.7046325206756592},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.536296546459198},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.5357524156570435},{"id":"https://openalex.org/C2775962371","wikidata":"https://www.wikidata.org/wiki/Q908096","display_name":"Opioid antagonist","level":5,"score":0.5096797943115234},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.49016913771629333},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.4897289574146271},{"id":"https://openalex.org/C14397066","wikidata":"https://www.wikidata.org/wiki/Q14911924","display_name":"\u03bc-opioid receptor","level":4,"score":0.41082531213760376},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3881192207336426},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.33565977215766907},{"id":"https://openalex.org/C2778750930","wikidata":"https://www.wikidata.org/wiki/Q4540629","display_name":"(+)-Naloxone","level":4,"score":0.2079406976699829},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12705007195472717},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001921","descriptor_name":"Brain","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006168","descriptor_name":"Guinea Pigs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006224","descriptor_name":"Cricetinae","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008024","descriptor_name":"Ligands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009019","descriptor_name":"Morphinans","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D009019","descriptor_name":"Morphinans","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D009019","descriptor_name":"Morphinans","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011869","descriptor_name":"Radioligand Assay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013237","descriptor_name":"Stereoisomerism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016466","descriptor_name":"CHO Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017473","descriptor_name":"Receptors, Opioid, kappa","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D020650","descriptor_name":"Combinatorial Chemistry Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm020084h","doi":"https://doi.org/10.1021/jm020084h","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm020084h","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:12139463","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12139463","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.4000000059604645,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3861717303","display_name":null,"funder_award_id":"DA 09045","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G6365479704","display_name":"Selective Opioid Antagonists as Medications for Drug Abuse","funder_award_id":"R01DA009045","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1971043777","https://openalex.org/W1978267774","https://openalex.org/W1980616516","https://openalex.org/W2004534561","https://openalex.org/W2014110722","https://openalex.org/W2038322363","https://openalex.org/W2044791824","https://openalex.org/W2091370368","https://openalex.org/W2531921652","https://openalex.org/W2952377621"],"related_works":["https://openalex.org/W1979505706","https://openalex.org/W2062407720","https://openalex.org/W2003464561","https://openalex.org/W2063795614","https://openalex.org/W2060491949","https://openalex.org/W2015615284","https://openalex.org/W2617693854","https://openalex.org/W2028679213","https://openalex.org/W7215132758","https://openalex.org/W2803982079"],"abstract_inverted_index":{"A":[0],"library":[1],"of":[2,46],"compounds":[3],"biased":[4],"toward":[5],"opioid":[6,39],"receptor":[7,40],"antagonist":[8,41],"activity":[9],"was":[10,30],"prepared":[11],"by":[12],"incorporating":[13],"N-phenylpropyl-4beta-methyl-5-(3-hydroxyphenyl)morphans":[14],"as":[15,32],"the":[16,33,43],"core":[17],"scaffold":[18],"using":[19],"simultaneous":[20],"solution":[21],"phase":[22],"synthetic":[23],"methodology.":[24],"From":[25],"this":[26],"library,":[27],"N-phenylpropyl-4beta-methyl-5-(3-hydroxyphenyl)-7alpha-[3-(1-piperidinyl)propanamido]morphan":[28],"[(-)-3b]":[29],"identified":[31],"first":[34],"potent":[35],"and":[36],"selective":[37],"kappa":[38],"from":[42],"5-phenylmorphan":[44],"class":[45],"opioids.":[47]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}